# ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

> **NCT03759340** · PHASE2 · TERMINATED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Alopecia Areata
- Alopecia Universalis
- Alopecia Totalis

## Interventions

- **DRUG:** ATI 502 0.46% Topical Solution

## Key facts

- **NCT ID:** NCT03759340
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-15
- **Primary completion:** 2019-09-11
- **Final completion:** 2019-09-11
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03759340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03759340, "ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03759340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*